Epigenetic therapies to differentiate and eradicate leukaemia stem cells

白血病干细胞（LSC）通常对常规和靶向治疗具有抗性，因此可作为白血病复发的种子。该项目的总体目标是使用小分子疗法来阻断LSC中特定蛋白质（LSD 1）的活性，以区分它们并暴露另一种称为BET抑制剂的表观遗传疗法的脆弱性。总之，这些表观遗传疗法将分化和根除LSC，从而改善AML的结局。

Leukemia stem cells (LSC) are often resistant to conventional and targeted therapies and therefore serve as the seed for leukaemia relapse. The overall aim of this project is to use small molecule therapies to block the activity of a particular protein (LSD1) in LSC in order to differentiate them and expose a vulnerability to another epigenetic therapy called a BET inhibitor. Together, these epigenetic therapies will differentiate and eradicate LSC, leading to improved outcome in AML.